Molecules 2012, 17(12), 14555-14564; doi:10.3390/molecules171214555
Article

Development and Validation of a Bioanalytical Method for Quantification of 2,6-Bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) in Rat Plasma

Yu Zhao Lee 1,† email, Lee Ming-Tatt 1,† , Nordin Hj Lajis 2 email, Mohd Roslan Sulaiman 1 email, Daud Ahmad Israf 1 email and Chau Ling Tham 1,* email
1 Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia 2 Scientific Chairs Unit, Taibah University, P.O. Box 30001, 41311 Madinah al Munawarah, Saudi Arabia † These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 10 October 2012; in revised form: 6 December 2012 / Accepted: 7 December 2012 / Published: 7 December 2012
PDF Full-text Download PDF Full-Text [340 KB, uploaded 7 December 2012 10:26 CET]
Abstract: A sensitive and accurate high performance liquid chromatography with ultraviolet/visible light detection (HPLC-UV/VIS) method for the quantification of 2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) in rat plasma was developed and validated. BHMC and the internal standard, harmaline, were extracted from plasma samples by a simple liquid–liquid extraction using 95% ethyl acetate and 5% methanol. Plasma concentration of BHMC and internal standard were analyzed by reversed phase chromatography using a C18 column (150 × 4.6 mm I.D., particle size 5 µm) and elution with a gradient mobile phase of water and methanol at a flow rate of 1.0 mL/min. Detection of BHMC and internal standard was done at a wavelength of 380 nm. The limit of quantification was 0.02 µg/mL. The calibration curves was linear (R2 > 0.999) over the concentration range of 0.02–2.5 µg/mL. Intra- and inter-day precision were less than 2% coefficient of variation. The validated method was then applied to a pharmacokinetic study in rats by intravenous administration of BHMC at a single dose of 10 mg/kg. Pharmacokinetic parameters such as half-life, maximum plasma concentration, volume of distribution, clearance and elimination rate constant for BHMC were calculated.
Keywords: BHMC; curcuminoid analogue; HPLC; pharmacokinetic; plasma extraction

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Lee, Y.Z.; Ming-Tatt, L.; Lajis, N.H.; Sulaiman, M.R.; Israf, D.A.; Tham, C.L. Development and Validation of a Bioanalytical Method for Quantification of 2,6-Bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) in Rat Plasma. Molecules 2012, 17, 14555-14564.

AMA Style

Lee YZ, Ming-Tatt L, Lajis NH, Sulaiman MR, Israf DA, Tham CL. Development and Validation of a Bioanalytical Method for Quantification of 2,6-Bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) in Rat Plasma. Molecules. 2012; 17(12):14555-14564.

Chicago/Turabian Style

Lee, Yu Z.; Ming-Tatt, Lee; Lajis, Nordin H.; Sulaiman, Mohd R.; Israf, Daud A.; Tham, Chau L. 2012. "Development and Validation of a Bioanalytical Method for Quantification of 2,6-Bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) in Rat Plasma." Molecules 17, no. 12: 14555-14564.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert